Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SCP-111 · 1 trial · 2 indications
Area under the plasma concentration-time curve from time 0 (pre-dose) to time of last measurable plasma concentration.
Area under the plasma concentration-time curve from time 0 (pre-dose) extrapolated to infinity.
The percentage of the AUC that is extrapolated beyond the last measurable concentration.
Maximum observed plasma concentration of Furosemide
Time of maximum observed Furosemide plasma concentration
Apparent plasma terminal-phase elimination rate constant
Terminal-phase half-life
Systemic clearance for IV furosemide (CL) and Apparent systemic clearance for SC furosemide (CL/F)
Systemic Volume of distribution, terminal phase for IV furosemide (V) and Apparent Volume of distribution, terminal phase for SC furosemide (Vz/F)
Total Urine Output from 0 to 6 hours
Total Urine Output from 0 to 8 hours
Total Urine Output from 0 to 12 hours
Urinary sodium excretion from 0 to 6 hours
Urinary sodium excretion from 0 to 8 hours
Urinary sodium excretion from 0 to 12 hours
Urinary potassium excretion from 0 to 6 hours
Urinary potassium excretion from 0 to 8 hours
Urinary potassium excretion from 0 to 12 hours
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | Period 1: SC Period 2: IV |
| Treatment Sequence 2 | EXPERIMENTAL | Period 1: IV Period 2: SC |
| Name | Type | Description |
|---|---|---|
| SCP-111 | DRUG | Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose |
| Furosemide USP | DRUG | Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later |
Inclusion Criteria: 1. An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities. 2. Male and female subjects 45 to 80 years of age. 3. Has the ability to understand the requirements of the study and is willing to comply with all study p...
Top 20 of 31 competitors
SCP-111 is an investigational small molecule being developed for heart failure, specifically to address fluid overload. It is a cardiovascular therapeutic candidate studied in a Phase 1 clinical trial. The drug is not yet approved and remains in clinical development.
SCP-111 is a small molecule intended for heart failure with fluid overload. Its mechanism involves pharmacokinetic and pharmacodynamic effects similar to furosemide, a loop diuretic, as evaluated in a clinical trial comparing subcutaneous and intravenous administration. The specific molecular target has not been disclosed.
SCP-111 is being developed by MannKind Corporation, a biopharmaceutical company listed on NASDAQ under the ticker MNKD. The company is conducting clinical research on this investigational cardiovascular drug candidate.
SCP-111 is in Phase 1 clinical development. A Phase 1 trial has been completed, evaluating the drug in healthy volunteers. SCP-111 is investigational and has not received FDA approval.
SCP-111 has one completed Phase 1 clinical trial, NCT06167707, titled 'Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers.' The trial enrolled 21 participants in the United States, with healthy volunteers aged 45 years and older.
SCP-111 is being studied in a trial that compares subcutaneous and intravenous furosemide, but SCP-111 itself is a distinct investigational drug candidate. The trial evaluates the pharmacokinetics and pharmacodynamics of these administration routes in healthy volunteers, and SCP-111 is not listed as an alternative name for furosemide.